References
- Arribas JR, Storch GA, Clifford DB, Tselis AC (1996). Cytomegalovirus encephalitis. Ann Intern Med 125:577–587.
- Berman SM, Kim RC (1994). The development of cytomegalovirus encephalitis in AIDS patients receiving ganciclovir. Am J Med 96:415–419.
- Hamprecht K, Eckle T, Prix L, Faul C, Einsele H, Jahn G (2003). Ganciclovir-resistant cytomegalovirus disease after allogeneic stem cell transplantation: pitfalls of phenotypic diagnosis by in vitro selection of an UL97 mutant strain. J Infect Dis 187:139–143.
- Holland NR, Power C, Mathews VP, Glass JD, Forman M, McArthur JC (1994). Cytomegalovirus encephalitis in acquired immunodeficiency syndrome (AIDS). Neurology 44(3 Pt 1): 507–514.
- Julin JE, van Burik JH, Krivit W, Webb C, Holman CJ, Clark HB, (2002). Ganciclovir-resistant cytomegalovirus encephalitis in a bone marrow transplant recipient. Transpl Infect Dis 4:201–206.
- Kalayjian RC, Cohen ML, Bonomo RA, Flanigan TP (1993). Cytomegalovirus ventriculoencephalitis in AIDS. A syndrome with distinct clinical and pathologic features. Medicine (Baltimore) 72:67–77.
- Kroger N, Zabelina T, Kruger W, Renges H, Stute N, Schrum J, (2001). Patient cytomegalovirus seropositivity with or without reactivation is the most important prognostic factor for survival and treatment-related mortality in stem cell transplantation from unrelated donors using pretransplant in vivo T-cell depletion with anti-thymocyte globulin. Br J Haematol 113:1060–1071.
- Leen AM, Myers GD, Sili U, Huls MH, Weiss H, Leung KS, (2006). Monoculture-derived T lymphocytes specific for multiple viruses expand and produce clinically relevant effects in immunocompromised individuals. Nat Med 12:1160–1166.
- Marr KA, Carter RA, Boeckh M, Martin P, Corey L (2002). Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 100:4358–4366.
- Mastroianni CM, Ciardi M, Folgori F, Sebastiani G, Vullo V, Delia S, (1994). Cytomegalovirus encephalitis in two patients with AIDS receiving ganciclovir for cytomegalovirus retinitis. J Infect 29:331–337.
- McCutchan JA (1995). Clinical impact of cytomegalovirus infections of the nervous system in patients with AIDS. Clin Infect Dis 21(Suppl 2): S196–S201.
- Meyers JD, Reed EC, Shepp DH, Thornquist M, Dandliker PS, Vicary CA, (1988). Acyclovir for prevention of cytomegalovirus infection and disease after allogeneic marrow transplantation. N Engl J Med 318:70–75.
- Miller GG, Boivin G, Dummer JS, McConnell T, Becher MW, Kassim A, (2006). Cytomegalovirus ventriculoencephalitis in a peripheral blood stem cell transplant recipient. Clin Infect Dis 42:e26–e29.
- Seo SK, Regan A, Cihlar T, Lin DC, Boulad F, George D, (2001). Cytomegalovirus ventriculoencephalitis in a bone marrow transplant recipient receiving antiviral maintenance: clinical and molecular evidence of drug resistance. Clin Infect Dis 33:e105–e108.
- Wolf DG, Lurain NS, Zuckerman T, Hoffman R, Satinger J, Honigman A, (2003). Emergence of late cytomegalovirus central nervous system disease in hematopoietic stem cell transplant recipients. Blood 101:463–465.
- Verdonck LF, Dekker AW, Rozenberg-Arska M, van den Hoek MR (1997). A risk-adapted approach with a short course of ganciclovir to prevent cytomegalovirus (CMV) pneumonia in CMV-seropositive recipients of allogeneic bone marrow transplants. Clin Infect Dis 24:901–907.